Go online to PeerView.com/MAJ860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, expert Richard S. Finn, MD, recaps the most important developments in the management of patients with hepatocellular carcinoma (HCC), including new data presented at the American Society for Clinical Oncology 2020 Annual Meeting, and provides his perspective on how new and emerging treatment strategies can be incorporated into clinical practice and improve outcomes. Upon completion of this activity, participants should be better able to: Describe the clinical evidence on available multikinase inhibitors and anti-angiogenic agents as first- and second-line treatment options for advanced HCC, Evaluate the validated and potential roles of immune checkpoint inhibitors, including strategies of monotherapy, dual checkpoint inhibition, and in combination with targeted therapy, in the advanced HCC disease setting, Review ongoing clinical trials investigating innovative strategies, including combinations of local modalities, such as TACE and TARE, with systemic therapies, such as targeted agents and checkpoint inhibitors, across the HCC disease spectrum, Select safe and effective treatments for patients with advanced HCC across multiple lines of therapy based on clinical evidence, practice guidelines, treatment history, disease factors, AFP levels, and patients’ needs.